Budesonide ameliorates early portal hypertension in the rat: Possible antiexudative splanchnic action

Inflammopharmacology

Volumn 11, Issue 3, 2003, Pages 211-222

  Vega De Ceniga M ^a   Valdes F ^a   Aller, M A ^b   Nava, M P ^b   Chivato, T ^c   Arias, J ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Hospital Militar del Aire   (Spain)

Author keywords

Budesonide; Inflammation; Prehepatic portal hypertension; Rat

Indexed keywords

BUDESONIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; EVOLUTION; EXUDATE; HYPOALBUMINEMIA; HYPOPROTEINEMIA; HYPOTHESIS; MALE; NONHUMAN; PANCREAS; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT; SPLANCHNIC BLOOD FLOW;

EID: 0042322209     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856003322315569     Document Type: Article

References (32)

1. Aller, M. A., Arias, J. L., Lorente, L., et al. (2001). Neuro-immune-endocrine functional system and vascular pathology, Med. Hypoth. 57, 561-569.
2. Barnes, P. J. (2001). Molecular mechanisms of corticosteroids in allergic diseases, Allergy 56, 928-936.
3. Carra, S., Gagliardi, L., Zanconato, S., et al. (2001). Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children, Respir. Med. 95, 734-739.
4. Chojkier, M. and Groszmann, R. J. (1981). Measurement of portal-systemic shunting in the rat using γ-labeled microspheres. Am. J. Physiol. 240, G371-G375.
5. Cines, D. B., Pollack, E. S., Buck, C. A., et al. (1998). Endothelial cells in physiology and in the pathophysiology of vascular disorders, Blood 91, 3527-3561.
6. Davies, P. F. and Tripathi, S. C. (1993). Mechanical stress mechanisms and the cell: an endothelial paradigm, Circ. Res. 72, 239-245.
7. Davies, M. G. and Hagen, P.-O. (1993). The vascular endothelium. A new horizon, Ann. Surg. 218, 593-609.
8. Diehl, A. M. and Rai, R. M. (1996). Regulation of signal transduction during liver regeneration, FASEB J. 10, 215-227.
9. Diehl, A. M. (2000). Cytokine regulation of liver injury and repair, Immunol. Rev. 174, 160-171.
10. Feizi, T. (1968). Serum immunoglobulins in liver disease, Gut 9, 193-198.
11. García-Cardeña, G., Comander, J., Anderson, K. R., et al. (2001). Biomechanical activation of vascular endothelium as a determinant of its functional phenotype, Proc. Natl. Acad. Sci. USA 98, 4478-4485.
12. Garcia-Tsao, G., Albillos, A., Barden, G. R., et al. (1993). Bacterial translocation in acute and chronic portal hypertension, Hepatology 17, 1081-1085.
13. Gomollón, F., Hinojosa, J. and Nos, P. (1999). Budesonida y enfermedad inflamatoria intestinal, Gastroenterol. Hepatol. 22, 525-532 (in Spanish).
14. Groszmann, R. J., Vorobioff, J. and Riley, E. (1982). Measurement of splanchnic hemodynamics in portal hypertensive rats: application of γ-labeled microspheres, Ant. J. Physiol. 24, G156-G160.
15. Gustafsson, B., Miller-Larsson, A. and Persson, C. G. A. (2001). Topical and oral anti-inflammatory activity of budesonide compared with oral prednisolone in an animal model using allergen-induced gut mucosal exudation of plasma as a marker, Scand. J. Gastroenterol. 36, 1062-1066.
16. Hamedani, R., Feldman, R. D. and Feagan, B. G. (1997). Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy, Aliment. Pharmacol. Ther. 11 (Suppl. 3), 98-107.
17. Hanauer, S. B. and Dassapoulos, T. (2001). Evolving treatment strategies for inflammatory bowel disease, Annu. Rev. Med. 52, 299-318.
18. Inagami, T., Naruse, M. and Hoover, R. (1995). Endothelium as an endocrine organ, Anu. Rev. Physiol. 57, 171-189.
19. 1-acid glycoprotein from liver, Can. J. Biochem. 51, 1281-1291.
20. Lin, H. C., Soubrane, O. and Lebrec, D. (1991a). Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats, Hepatology 14, 325-330.
21. Lin, H. C., Soubrane, O., Cailmal, S., et al. (1991b). Early chronic administration of propanolol reduces the severity of portal hypertension and portal-systemic shunt in conscious portal vein stenosed rats, J. Hepatol. 13, 213-219.
22. Lin, H. C., Yang, M. C.-H., Hou, M.-C., et al. (1996). Effects of long-term administration of octreotide in portal vein-stenosed rats, Hepatology 23, 537-543.
23. Lum, H. and Malik, A. B. (1994). Regulation of vascular endothelial barrier function, Am. J. Physiol. 267, L223-L241.
24. 4 levels in short-term prehepatic portal hypertension in rats, Dig. Dis. Sci. 45, 1865-1871.
25. O'Connor, T. M., O'Halloran, D. J. and Shanahan, F. (2000). The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia, Q. J. Med. 93, 323-333.
26. Owen, J. A. and Robertson, R. F. (1956). Payer electrophoresis on serum proteins in hepatoliliary disease, Lancet 2, 1125-1132.
27. Rodríguez-Gómez, J., Rodrfguez-Fabian, G. and Aller, M. A. (2000). Normas éticas para el cuidado y utilización de los animales de experimentación, Circ. Esp. 67, 10-13.
28. Sherlock, S. (1989). Assessment of liver function, in: Diseases of the Liver and Biliary System, 8th edn, pp. 19-35. Blackwell, Oxford.
29. Sikuler, E., Kravetz, D. and Groszmann, R. J. (1985). Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model, Am. J. Physiol. 248, G618-G625.
30. Sorell, W. T., Quigley, E. M., Jin, G., et al. (1993). Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock, Gastroenterology 104, 1722-1726.
31. Spencer, C. M. and McTavish, D. (1995). Budesonide: A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel diseases, Drugs 50, 854-872.
32. Vorobioff, J. E., Bredfeldt, J. E., Groszmann, R. J. (1983). Hyperdynamic circulation in portalhypertensive rat model: a primary factor for maintenance of chronic portal hypertension, Am. J. Physiol. 244, G52-G57.